{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:30:15Z","timestamp":1762507815702},"reference-count":80,"publisher":"Bentham Science Publishers Ltd.","issue":"2","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRP"],"published-print":{"date-parts":[[2019,7,16]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Pancreatic Neuroendocrine Tumors (P-NETs) are a challenge in terms of both diagnosis and therapy; morphological studies need to be frequently implemented with nonstandard techniques such as Endoscopic Ultrasounds, Dynamic CT, and functional Magnetic Resonance.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion:<\/jats:title><jats:p>The role of nuclear medicine, being scarcely sensitive F-18 Fluorodeoxyglucose, is mainly based on the over-expression of Somatostatin Receptors (SSTR) on neuroendocrine tumor cells surface. Therefore, SSTR can be used as a target for both diagnosis, using radiotracers labeled with gamma or positron emitters, and therapy. SSTRs subtypes are capable of homo and heterodimerization in specific combinations that alter both the response to ligand activation and receptor internalization.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Although agonists usually provide efficient internalization, also somatostatin antagonists (SS-ANTs) could be used for imaging and therapy. Peptide Receptor Radionuclide Therapy (PRRT) represents the most successful option for targeted therapy. The theranostic model based on SSTR does not work in insulinoma, in which different radiotracers such as F-18 FluoroDOPA or tracers for the glucagon-like peptide-1 receptor have to be preferred.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1874471012666190206094555","type":"journal-article","created":{"date-parts":[[2019,7,21]],"date-time":"2019-07-21T13:13:53Z","timestamp":1563714833000},"page":"98-106","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Physiopathological Premises to Nuclear Medicine Imaging of Pancreatic Neuroendocrine Tumours"],"prefix":"10.2174","volume":"12","author":[{"given":"Vincenzo","family":"Cuccurullo","sequence":"first","affiliation":[{"name":"Nuclear Medicine Unit, Department of Clinical and Experimental Medicine \"F.Magrassi, A.Lanzara\" \u2013 Universita della Campania \"Luigi Vanvitelli\", Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe Danilo","family":"Di Stasio","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Clinical and Experimental Medicine \"F.Magrassi, A.Lanzara\" \u2013 Universita della Campania \"Luigi Vanvitelli\", Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Mansi","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Unit, Department of Clinical and Experimental Medicine \"F.Magrassi, A.Lanzara\" \u2013 Universita della Campania \"Luigi Vanvitelli\", Napoli, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1053\/j.semdp.2014.08.008","volume":"6","author":"Shi C.","year":"2014","unstructured":"Shi C, Klimstra DS. Semin Diagn Pathol, Pancreatic neuroendocrine tumors: Pathologic and molecular characteristics.,, 2014, 6,, 498-511,","journal-title":"Semin Diagn Pathol"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"457","DOI":"10.21037\/jgo.2016.12.09","volume":"3","author":"Liu I.H.","year":"2017","unstructured":"Liu IH, Kunz PL. J Gastrointest Oncol, Biologics in gastrointestinal and pancreatic neuroendocrine tumors.,, 2017, 3,, 457-465,","journal-title":"J Gastrointest Oncol"},{"key":"ref=3","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1007\/s12022-014-9313-z","volume":"2","author":"Rindi G.","year":"2014","unstructured":"Rindi G, Petrone G, Inzani F. Endocr Pathol, The 2010 WHO classification of digestive neuroendocrine neoplasms: A critical appraisal four years after its introduction.,, 2014, 2,, 186-192,","journal-title":"Endocr Pathol"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12022-013-9295-2","volume":"1","author":"Reid M.D.","year":"2014","unstructured":"Reid MD, Balci S, Saka B, Adsay NV. Endocr Pathol, Neuroendocrine tumors of the pancreas: Current concepts and controversies.,, 2014, 1,, 65-79,","journal-title":"Endocr Pathol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.bpg.2012.12.004","volume":"6","author":"Sundin A.","year":"2012","unstructured":"Sundin A. Best Pract Res Clin Gastroenterol, Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours.,, 2012, 6,, 803-818,","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref=6","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.3109\/0284186X.2014.941999","volume":"53","author":"Janson E.T.","year":"2014","unstructured":"Janson ET, Sorbye H, Welin S, Federspiel B, Gronbaek H, Hellman P, Ladekarl M, Langer SW, Mortensen J, Schalin-Jantti C, Sundin A, Sundlov A, Thiis-Evensen E, Knigge U. Acta Oncologica, Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.,, 2014, 53,, 1284-1297,","journal-title":"Acta Oncologica"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/RCT.0000000000000140","volume":"38","author":"Jacobs M.A.","year":"2014","unstructured":"Jacobs MA, Weinstein S, Hope TA, Aslam R, Yee J, Coakley F. J Comput Assist Tomogr, Neuroendocrine tumors: Beyond the abdomen.,, 2014, 38,, 898-8914,","journal-title":"J Comput Assist Tomogr"},{"key":"ref=8","doi-asserted-by":"crossref","first-page":"9512","DOI":"10.3748\/wjg.v21.i32.9512","volume":"21","author":"Cloyd J.M.","year":"2015","unstructured":"Cloyd JM, Poultsides GA. World J Gastroenterol, Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.,, 2015, 21,, 9512-9525,","journal-title":"World J Gastroenterol"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1159\/000358727","volume":"99","author":"Toumpanakis C.","year":"2014","unstructured":"Toumpanakis C, Kim MK, Rinke A, Bergestuen DS, Thirlwell C, Khan MS, Salazar R, Oberg K. Neuroendocrinology, Combination of cross-sectional and molecular imaging studies in the localization of gastroenteropancreatic neuroendocrine tumors.,, 2014, 99,, 63-74,","journal-title":"Neuroendocrinology"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"R173","DOI":"10.1530\/EJE-14-0077","volume":"170","author":"de Herder W.W.","year":"2014","unstructured":"de Herder WW. Eur J Endocrinol, GEP-NETS update: Functional localisation and scintigraphy in neuroendocrine tumours of the gastrointestinal tract and pancreas (GEP-NETs).,, 2014, 170,, R173-R183,","journal-title":"Eur J Endocrinol"},{"key":"ref=11","first-page":"367","volume":"37","author":"Cuccurullo V.","year":"2012","unstructured":"Cuccurullo V, Faggiano A, Scialpi M, Cascini GL, Piunno A, Catalano O, Colao A, Mansi L. Minerva Endocrinol, Questions and answers: What can be said by diagnostic imaging in neuroendocrine tumors?,, 2012, 37,, 367-377,","journal-title":"Minerva Endocrinol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/1874471011306010006","volume":"6","author":"Cascini G.L.","year":"2013","unstructured":"Cascini GL, Cuccurullo V, Tamburrini O, Rotondo A, Mansi L. Curr Radiopharm, Peptide imaging with somatostatin analogues: More than cancer probes.,, 2013, 6,, 36-40,","journal-title":"Curr Radiopharm"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1006\/frne.1999.0183","volume":"20","author":"Patel Y.E.","year":"1999","unstructured":"Patel YE. Front Neuroendocrinol, Somatostatin and its receptor family.,, 1999, 20,, 157-198,","journal-title":"Front Neuroendocrinol"},{"key":"ref=14","first-page":"1922","volume":"56","author":"Reubi J.C.","year":"1996","unstructured":"Reubi JC, Waser B, Laissue JA, Gebbers J-O. Cancer Res, Somatostatin and vasoactive intestinal peptide receptors in human mesenchymal tumors: identification.,, 1996, 56,, 1922-19231,","journal-title":"Cancer Res"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1210\/er.2002-0007","volume":"24","author":"Reubi J.C.","year":"2003","unstructured":"Reubi JC. Endocr Rev, Peptide receptors as molecular targets for cancer diagnosis and therapy.,, 2003, 24,, 389-427,","journal-title":"Endocr Rev"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.2967\/jnumed.114.147082","volume":"55","author":"Mansi L.","year":"2014","unstructured":"Mansi L, Cuccurullo V. Soc Nucl Med, Diagnostic imaging in neuroendocrine tumors. .: Official publication.,, 2014, 55,, 1576-1577,","journal-title":"Soc Nucl Med"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1007\/s002590100541","volume":"28","author":"Reubi J.C.","year":"2001","unstructured":"Reubi JC, Waser B, Schaer JC, Laissue JA. Eur J Nucl Med, Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands.,, 2001, 28,, 836-846,","journal-title":"Eur J Nucl Med"},{"key":"ref=18","first-page":"2942","volume":"84","author":"Reubi J.C.","year":"1999","unstructured":"Reubi JC, Laissue JA, Waser B, Steffen DL, Hipkin RW, Schonbrunn A. J Clin Endocrinol Metab, Immunohistochemical detection of somatostatin sst2a receptors in the lymphatic, smooth muscular, and peripheral nervous systems of the human gastrointestinal tract: Facts and artifacts.,, 1999, 84,, 2942-2950,","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00259-003-1184-3","volume":"30","author":"Reubi J.C.","year":"2003","unstructured":"Reubi JC, Waser B. Eur J Nucl Med Mol Imaging, Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for multireceptortumour targeting.,, 2003, 30,, 781-793,","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1385\/ENDO:20:3:255","volume":"20","author":"Barnett P.","year":"2003","unstructured":"Barnett P. Endocrine, Somatostatin and somatostatin receptor physiology.,, 2003, 20,, 255-264,","journal-title":"Endocrine"},{"key":"ref=21","first-page":"24","volume":"54","author":"Cascini G.L.","year":"2010","unstructured":"Cascini GL, Cuccurullo V, Mansi L. Q J Nucl Med Mol Imaging, The non tumour uptake of (111)In-octreotide creates new clinical indications in benign diseases, but also in oncology.,, 2010, 54,, 24-36,","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1530\/eje.1.01901","volume":"152","author":"Vezzosi D.","year":"2005","unstructured":"Vezzosi D, Bennet A, Rochaix P, Courbon F, Selves J, Pradere B, Buscail L, Susini C, Caron P. Eur J Endocrinol, Octreotide in insulinoma patients: efficacy on hypoglycemia, relationships with Octreoscan scintigraphy and immunostaining with anti-sst2A and anti-sst5 antibodies.,, 2005, 152,, 757-767,","journal-title":"Eur J Endocrinol"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s002590050034","volume":"27","author":"Reubi J.C.","year":"2000","unstructured":"Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS. Eur J Nucl Med, Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use.,, 2000, 27,, 273-282,","journal-title":"Eur J Nucl Med"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1210\/jc.2008-1919","volume":"94","author":"Lesche S.","year":"2009","unstructured":"Lesche S, Lehmann D, Nagel F, Schmid HA, Schulz S. J Clin Endocrinol Metab, Differential effects of octreotide and pasireotide on somatostatin receptor internalization and trafficking ,, 2009, 94,, 654-661,","journal-title":"J Clin Endocrinol Metab"},{"key":"ref=25","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1053\/j.semnuclmed.2012.01.002","volume":"42","author":"Baum R.P.","year":"2012","unstructured":"Baum RP, Kulkarni HR, Carreras C. Seminars Nucl Med, Peptides and receptors in image-guided therapy: theranostics for neuroendocrine neoplasms.,, 2012, 42,, 190-207,","journal-title":"Seminars Nucl Med"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","volume":"17","author":"Kwekkeboom D.J.","year":"2010","unstructured":"Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP. Endocr Relat Cancer, Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.,, 2010, 17,, R53-R573,","journal-title":"Endocr Relat Cancer"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/annonc\/10.suppl_2.S23","volume":"10","author":"Krenning E.P.","year":"1999","unstructured":"Krenning EP, de Jong M, Kooij PP, Breeman WA, Bakker WH, de Herder WW, van Eijck CH, Kwekkeboom DJ, Jamar F, Pauwels S, Valkema R. Ann Oncol, Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.,, 1999, 10,, S23-S239,","journal-title":"Ann Oncol"},{"key":"ref=28","first-page":"502","volume":"47","author":"Cescato R.","year":"2006","unstructured":"Cescato R, Schulz S, Waser B, Eltschinger V, Rivier JE, Wester HJ, Culler M, Ginj M. J Nucl Med, Liu. Q.; Schonbrunn, A.; Reubi, J.C. Internalization of sst2, sst3 and sst5 recep- tors: effects of somatostatin agonists and antagonists.,, 2006, 47,, 502-511,","journal-title":"J Nucl Med"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF03345728","volume":"32","author":"Bodei L.","year":"2009","unstructured":"Bodei L, Ferone D, Grana CM, Cremonesi M, Signore A, Dierckx RA, Paganelli G. J Endocrinol Invest, Peptide receptortherapies in Neuroendocrine tumors.,, 2009, 32,, 360-369,","journal-title":"J Endocrinol Invest"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2174\/1874471011306020001","volume":"6","author":"Kitson S.L.","year":"2013","unstructured":"Kitson SL, Cuccurullo V, Moody TS, Mansi L. Curr Radiopharm, Radionuclide antibody-conjugates, a targeted therapy towards cancer.,, 2013, 6,, 57-71,","journal-title":"Curr Radiopharm"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"61S","DOI":"10.2967\/jnumed.116.186783","volume":"58","author":"Fani M.","year":"2017","unstructured":"Fani M, Nicolas GP, Wild D. J Nucl Med, Somatostatin receptor antagonists for imaging and therapy.,, 2017, 58,, 61S-66S,","journal-title":"J Nucl Med"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.tips.2017.04.002","volume":"38","author":"Kliewer A.","year":"2017","unstructured":"Kliewer A, Reinscheid RK, Schulz S. Trends Pharmacol Sci, Emerging paradigms of G protein-coupled receptor dephosphorylation.,, 2017, 38,, 621-636,","journal-title":"Trends Pharmacol Sci"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nature17154","volume":"31","author":"Lee M.H.","year":"2016","unstructured":"Lee MH, Appleton KM, Strungs EG, Kwon JY, Morinelli TA, Peterson YK, Laporte SA, Luttrell LM. Nature, The conformational signature of \u03b2-arrestin2 predicts its trafficking and signalling functions.,, 2016, 31,, 665-668,","journal-title":"Nature"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1530\/eje.1.02307","volume":"155","author":"O\u2019Toole D.","year":"2006","unstructured":"O\u2019Toole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P, Ruszniewski P, Barlier A. Eur J Endocrinol, The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies.,, 2006, 155,, 849-857,","journal-title":"Eur J Endocrinol"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"54S","DOI":"10.2967\/jnumed.117.191015","volume":"58","author":"Smit Duijzentkunst D.A.","year":"2017","unstructured":"Smit Duijzentkunst DA, Kwekkeboom DJ, Bodei L. J Nucl Med, Somatostatin Receptor 2-Targeting Compounds.,, 2017, 58,, 54S-60S,","journal-title":"J Nucl Med"},{"key":"ref=36","first-page":"22","volume":"2","author":"Tornesello A.L.","year":"2017","unstructured":"Tornesello AL, Buonaguro L, Tornesello ML, Buonaguro FM. Molecules, New insights in the design of bioactive peptides and chelating agents for imaging and therapy in oncology.,, 2017, 2,, 22-28,","journal-title":"Molecules"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2174\/1874471010666170323115136","volume":"10","author":"Cuccurullo V.","year":"2017","unstructured":"Cuccurullo V, Prisco MR, Di Stasio GD, Mansi L. Curr Radiopharm, Nuclear medicine in patients with net: Radiolabeled somatostatin analogues and their brothers.,, 2017, 10,, 74-84,","journal-title":"Curr Radiopharm"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1385\/ENDO:20:3:307","volume":"20","author":"Van der Lely A.J.","year":"2003","unstructured":"Van der Lely AJ, de Herder WW, Krenning EP, Kwekkeboom DJ. Endocrine, Octreoscan radioreceptor imaging.,, 2003, 20,, 307-311,","journal-title":"Endocrine"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"R53","DOI":"10.1677\/ERC-09-0078","volume":"29","author":"Kwekkeboom D.J.","year":"2010","unstructured":"Kwekkeboom DJ, Kam BL, van Essen M, Teunissen JJ, van Eijck CH, Valkema R, de Jong M, de Herder WW, Krenning EP. Endocr Relat Cancer, Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.,, 2010, 29,, R53-R73,","journal-title":"Endocr Relat Cancer"},{"key":"ref=40","first-page":"225","volume":"49","author":"Rambaldi P.F.","year":"2005","unstructured":"Rambaldi PF, Cuccurullo V, Briganti V, Mansi L. Q J Nucl Med Mol Imaging, The present and future role of (111)Inpentetreotide in the PET era.,, 2005, 49,, 225-235,","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00259-012-2156-2","volume":"39","author":"Cuccurullo V.","year":"2012","unstructured":"Cuccurullo V, Mansi L. Eur J Nucl Med Mol Imaging, Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model.,, 2012, 39,, 1262-1265,","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=42","first-page":"140","volume":"59","author":"Upadhyay B.","year":"2015","unstructured":"Upadhyay B, Lu SJ, Navalkissoor S, Gnanasegaran G, Buscombe J. Q J Nucl Med Mol Imaging, The imaging of neuroendocrine tumors using single photon emission computed tomography\/computed tomography.,, 2015, 59,, 140-151,","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1053\/j.semnuclmed.2006.03.007","volume":"36","author":"Rufini V.","year":"2006","unstructured":"Rufini V, Calcagni ML, Baum RP. Semin Nucl Med, Imaging of neuroendocrine tumors.,, 2006, 36,, 228-247,","journal-title":"Semin Nucl Med"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1089\/10849780152752119","volume":"16","author":"Briganti V.","year":"2001","unstructured":"Briganti V, Matteini M, Ferri P, Vaggelli L, Castagnoli A, Pieroni C. Cancer Biother Radiopharm, Octreoscan SPET evaluation in the diagnosis of pancreas neuroendocrine tumors.,, 2001, 16,, 515-524,","journal-title":"Cancer Biother Radiopharm"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1007\/s00259-010-1487-0","volume":"37","author":"Rambaldi P.F.","year":"2010","unstructured":"Rambaldi PF, Cuccurullo V, Cascini GL, Mansi L. Eur J Nucl Med Imaging, Our experience in thymic hyperplasia using 67Ga-citrate, 111In-pentetreotide and 201Tl-chloride.,, 2010, 37,, 1616-,","journal-title":"Eur J Nucl Med Imaging"},{"key":"ref=46","first-page":"32","volume":"13","author":"Cascini G.L.","year":"2010","unstructured":"Cascini GL, Cuccurullo V, Tamburrini O, Mansi L, Rotondo A. Nucl Med Review, Nuclear medicine in multiple myeloma - more thandiagnosis.,, 2010, 13,, 32-38,","journal-title":"Nucl Med Review"},{"key":"ref=47","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00259-012-2156-2","volume":"39","author":"Cuccurullo V.","year":"2012","unstructured":"Cuccurullo V, Mansi L. Eur J Nucl Med Mol Imaging, Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model.,, 2012, 39,, 1262-1265,","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=48","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2967\/jnumed.109.069765","volume":"51","author":"Binderup T.","year":"2010","unstructured":"Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, Hansen CP, Hojgaard L, Kjaer A. J Nucl Med, Functional imaging of neuroendocrine tumors: a head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET.,, 2010, 51,, 704-712,","journal-title":"J Nucl Med"},{"key":"ref=49","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1007\/s00259-014-2765-z","volume":"41","author":"Mansi L.","year":"2014","unstructured":"Mansi L, Cuccurullo V, Ciarmiello A. Eur J Nucl Med Mol Imaging, From Homo sapiens to Homo in nexu (connected man): Could functional imaging redefine the brain of a \u201cnew human species\u201d?,, 2014, 41,, 1385-1387,","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=50","doi-asserted-by":"crossref","first-page":"41","DOI":"10.2174\/1874471011306010007","volume":"6","author":"Cuccurullo V.","year":"2013","unstructured":"Cuccurullo V, Cascini GL, Tamburrini O, Rotondo A, Mansi L. Curr Radiopharm, Bone metastasesradiopharmaceuticals: An overview.,, 2013, 6,, 41-47,","journal-title":"Curr Radiopharm"},{"key":"ref=51","first-page":"41","volume":"36","author":"Cuccurullo V.","year":"2011","unstructured":"Cuccurullo V, Cascini GL, Tamburrini O, Mansi L, Rotondo A. Minerva Endocrinol, Less frequent requests for In-111 pentreotide and its brothers of endocrinological interest.,, 2011, 36,, 41-52,","journal-title":"Minerva Endocrinol"},{"key":"ref=52","doi-asserted-by":"crossref","first-page":"126","DOI":"10.5603\/NMR.2016.0024","volume":"19","author":"Miko\u0142ajczak R.","year":"2016","unstructured":"Miko\u0142ajczak R, Maecke HR. Nucl Med Rev Cent East Eur, Radiopharmaceuticals for somatostatin receptor imaging.,, 2016, 19,, 126-132,","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"ref=53","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2174\/1871520616666160926115008","volume":"17","author":"Kitson S.L.","year":"2017","unstructured":"Kitson SL, Cuccurullo V, Ciarmiello A, Mansi L. Anticancer Agents Med Chem, Targeted Therapy Towards Cancer-A Perspective.,, 2017, 17,, 311-317,","journal-title":"Anticancer Agents Med Chem"},{"key":"ref=54","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1002\/jcp.25478","volume":"232","author":"Cuccurullo V.","year":"2017","unstructured":"Cuccurullo V, Di Stasio GD, Evangelista L, Castoria G, Mansi L. J Cell Physiol, Biochemical and pathophysiological premises to positron emission tomography with choline radiotracers.,, 2017, 232,, 270-275,","journal-title":"J Cell Physiol"},{"key":"ref=55","first-page":"102","volume":"9","author":"Cuccurullo V.","year":"2016","unstructured":"Cuccurullo V, Di Stasio GD, Schillir\u00f2 ML, Mansi L. Curr Radiopharm, Small-animal molecular imaging for preclinical cancer research: PET and SPECT.,, 2016, 9,, 102-113,","journal-title":"Curr Radiopharm"},{"key":"ref=56","doi-asserted-by":"crossref","first-page":"12913","DOI":"10.3390\/molecules200712913","volume":"20","author":"Velikyan I.","year":"2015","unstructured":"Velikyan I. Molecules, 68Ga-Based radiopharmaceuticals: Production and application relationship.,, 2015, 20,, 12913-12943,","journal-title":"Molecules"},{"key":"ref=57","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.cpet.2013.08.016","volume":"9","author":"Kulkarni H.R.","year":"2014","unstructured":"Kulkarni HR, Baum RP. PET Clin, Theranostics with Ga-68 somatostatin receptor PET\/CT: monitoring response to peptide receptor radionuclide therapy.,, 2014, 9,, 91-97,","journal-title":"PET Clin"},{"key":"ref=58","first-page":"70","volume":"76","author":"Eberlein U.","year":"2013","unstructured":"Eberlein U, Lassmann M. PET Clin, Dosimetry of [(6)(8)Ga]-labeled compounds. Applied Radiation and Isotopes: Including data, instrumentation and methods for use in agriculture, industry and medicine,, 2013, 76,, 70-74,"},{"key":"ref=59","first-page":"58","volume":"59","author":"Ambrosini V.","year":"2015","unstructured":"Ambrosini V, Morigi JJ, Nanni C, Castellucci P, Fanti S. Q J Nucl Med Mol Imaging, Current status of PET imaging of neuroendocrine tumours ([18F]FDOPA, [68Ga]tracers, [11C]\/[18F]-HTP).,, 2015, 59,, 58-69,","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref=60","first-page":"244","volume":"51","author":"Win Z.","year":"2007","unstructured":"Win Z, Al-Nahhas A, Rubello D, Gross MD. Q J Nucl Med Mol Imaging, Somatostatin receptor PET imaging with Gallium-68 labeled peptides.,, 2007, 51,, 244-250,","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref=61","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.cpet.2014.03.008","volume":"9","author":"Ambrosini V.","year":"2014","unstructured":"Ambrosini V, Nanni C, Fanti S. PET Clin, The use of gallium-68 labeled somatostatin receptors in PET\/CT imaging.,, 2014, 9,, 323-329,","journal-title":"PET Clin"},{"key":"ref=62","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.2967\/jnumed.109.066639","volume":"50","author":"Kayani I.","year":"2009","unstructured":"Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, Bomanji JB. J Nucl Med, A comparison of 68Ga-DOTATATE and 18F-FDG PET\/CT in pulmonary neuroendocrine tumors.,, 2009, 50,, 1927-1932,","journal-title":"J Nucl Med"},{"key":"ref=63","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1007\/s00259-009-1205-y","volume":"37","author":"Prasad V.","year":"2010","unstructured":"Prasad V, Ambrosini V, Hommann M, Hoersch D, Fanti S, Baum RP. Eur J Nucl Med Mol Imaging, Detection of unknown primary neuroendocrine tumours (CUP-NET) using (68)Ga-DOTA-NOC receptor PET\/CT.,, 2010, 37,, 67-77,","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=64","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2217\/14796694.5.1.75","volume":"5","author":"Goldsmith S.J.","year":"2009","unstructured":"Goldsmith SJ. Future Oncol, Update on nuclear medicine imaging of neuroendocrine tumors.,, 2009, 5,, 75-84,","journal-title":"Future Oncol"},{"key":"ref=65","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1158\/1078-0432.1136.11.3","volume":"11","author":"Ginj M.","year":"2005","unstructured":"Ginj M, Chen J, Walter MA, Eltschinger V, Reubi JC, Maecke HR. Clin Cancer Res, Preclinical evaluation of new and highly potent analogues of octreotide for predictive imaging and targeted radiotherapy.,, 2005, 11,, 1136-1145,","journal-title":"Clin Cancer Res"},{"key":"ref=66","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1158\/1078-0432.CCR-07-1687","volume":"14","author":"Ginj M.","year":"2008","unstructured":"Ginj M, Zhang H, Eisenwiener KP, Wild D, Schulz S, Rink H, Cescato R, Reubi JC, Maecke HR. Clin Cancer Res, New pansomatostatin ligands and their chelated versions: affinity profile, agonist activity, internalization, and tumor targeting.,, 2008, 14,, 2019-2027,","journal-title":"Clin Cancer Res"},{"key":"ref=67","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1007\/s00259-013-2570-0","volume":"40","author":"Beyer T.","year":"2013","unstructured":"Beyer T, Hacker M, Schubiger A, Virgolini I, Wester HJ. European journal of nuclear medicine and molecular imaging, Nuclear medicine 2013: From status quo to status go.,, 2013, 40,, 1794-1796,","journal-title":"European journal of nuclear medicine and molecular imaging"},{"key":"ref=68","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s00259-015-3153-z","volume":"42","author":"Virgolini I.","year":"2015","unstructured":"Virgolini I, Innsbruck T. Eur J Nucl Med Mol Imaging, Peptide receptor radionuclide therapy (PRRT): clinical significance of re-treatment?,, 2015, 42,, 1949-1954,","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=69","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.thorsurg.2014.04.005","volume":"24","author":"Bodei L.","year":"2014","unstructured":"Bodei L, Cremonesi M, Kidd M, Grana CM, Severi S, Modlin IM, Paganelli G. Thorac Surg Clin, Peptide receptor radionuclide therapy for advanced neuroendocrine tumors.,, 2014, 24,, 333-349,","journal-title":"Thorac Surg Clin"},{"key":"ref=70","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/978-3-642-27994-2_27","volume":"194","author":"Sowa-Staszczak A.","year":"2013","unstructured":"Sowa-Staszczak A, Hubalewska-Dydejczyk A, Tomaszuk M. Recent Results Cancer Res, PRRT as neoadjuvant treatment in NET.,, 2013, 194,, 479-485,","journal-title":"Recent Results Cancer Res"},{"key":"ref=71","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/his.12808","volume":"68","author":"Del Gobbo A.","year":"2016","unstructured":"Del Gobbo A, Pellegrinelli A, Gaudioso G, Castellani M, Zito Marino F, Franco R, Palleschi A, Nosotti M, Bosari S, Vaira V, Ferrero S. Histopathology, Analysis of NSCLC tumourheterogeneity, proliferative and 18F-FDG PET indices reveals Ki67 prognostic role in adenocarcinomas.,, 2016, 68,, 746-751,","journal-title":"Histopathology"},{"key":"ref=72","first-page":"265","volume":"50","author":"Bakker W.H.","year":"2006","unstructured":"Bakker WH, Breeman WA, Kwekkeboom DJ, De Jong LC, Krenning EP. Q J Nucl Med Mol Imaging, Practical aspects of peptide receptor radionuclide therapy with [177Lu][DOTA0, Tyr3]octreotate.,, 2006, 50,, 265-2671,","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"ref=73","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.cpet.2015.06.001","volume":"10","author":"Taieb D.","year":"2015","unstructured":"Taieb D, Garrigue P, Bardies M, Abdullah AE, Pacak K. PET Clin, Application and dosimetric requirements for gallium-68-labeled somatostatin analogues in targeted radionuclide therapy for gastroenteropancreatic neuroendocrine tumors.,, 2015, 10,, 477-486,","journal-title":"PET Clin"},{"key":"ref=74","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.2967\/jnumed.110.076695","volume":"51","author":"Fani M.","year":"2010","unstructured":"Fani M, Mueller A, Tamma ML, Nicolas G, Rink HR, Cescato R, Reubi JC, Maecke HR. J Nucl Med, Radiolabeled bicyclic somatostatin-based analogs: A novel class of potential radiotracers for SPECT\/PET of neuroendocrine tumors.,, 2010, 51,, 1771-1779,","journal-title":"J Nucl Med"},{"key":"ref=75","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/2191-219X-2-25","volume":"2","author":"Tatsi A.","year":"2012","unstructured":"Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA. EJNMMI Res, 111In-DOTA-Somatostatin-14 analogs as potential pansomatostatin-like radiotracers - first results of a preclinical study.,, 2012, 2,, 25-28,","journal-title":"EJNMMI Res"},{"key":"ref=76","doi-asserted-by":"crossref","first-page":"6564","DOI":"10.1021\/jm500581d","volume":"57","author":"Maina T.","year":"2014","unstructured":"Maina T, Cescato R, Waser B, Tatsi A, Kaloudi A, Krenning EP, de Jong M, Nock BA, Reubi JC. J Med Chem, [111In-DOTA]LTT-SS28, a first pansomatostatin radioligand for targeting of somatostatin receptor-positive tumors.,, 2014, 57,, 6564-6571,","journal-title":"J Med Chem"},{"key":"ref=77","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.ejmech.2013.12.003","volume":"12","author":"Tatsi A.","year":"2014","unstructured":"Tatsi A, Maina T, Cescato R, Waser B, Krenning EP, de Jong M, Cordopatis P, Reubi JC, Nock BA. Eur J Med Chem, [DOTA]Somatostatin-14 analogs and their (111)In-radioligands: effects of decreasing ring-size on sst1-5 profile, stability and tumor targeting.,, 2014, 12,, 30-37,","journal-title":"Eur J Med Chem"},{"key":"ref=78","first-page":"459","volume":"41","author":"Schillaci O.","year":"2000","unstructured":"Schillaci O, Massa R, Scopinaro F. J Nucl Med, 111In-pentetreotide scintigraphy in the detection of insulinomas: Importance of SPECT imaging.,, 2000, 41,, 459-462,","journal-title":"J Nucl Med"},{"key":"ref=79","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s00259-016-3331-7","volume":"43","author":"Prasad V.","year":"2016","unstructured":"Prasad V, Sainz-Esteban A, Arsenic R, Pl\u00f6ckinger U, Denecke T, Pape UF, Pascher A, K\u00fchnen P, Pavel M, Blankenstein O. Eur J Nucl Med Mol Imaging, Role of (68)Ga somatostatin receptor PET\/CT in the detection of endogenous hyperinsulinaemic focus: An explorative study.,, 2016, 43,, 1593-1600,","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref=80","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1007\/s00259-012-2299-1","volume":"40","author":"Sowa-Staszczak A.","year":"2013","unstructured":"Sowa-Staszczak A, Pach D, Miko\u0142ajczak R, M\u00e4cke H, Jabrocka-Hybel A, Stefa\u0144ska A, Tomaszuk M, Janota B, Gilis-Januszewska A, Ma\u0142ecki M, Kami\u0144ski G, Kowalska A, Kulig J, Matyja A, Osuch C, Hubalewska-Dydejczyk A. Eur J Nucl Med Mol Imaging, Glucagon-like peptide-1 receptor imaging with [Lys40(Ahx-HYNIC- 99mTc\/EDDA)NH2]-exendin-4 for the detection of insulinoma.,, 2013, 40,, 524-531,","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Current Radiopharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/169635","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,24]],"date-time":"2022-09-24T09:04:16Z","timestamp":1664010256000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/169635\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,16]]},"references-count":80,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,7,16]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1874471012666190206094555","relation":{},"ISSN":["1874-4710"],"issn-type":[{"value":"1874-4710","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,16]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-01-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-02-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-10-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}